Initial Enrollment Period (IEP)

Initial Enrollment Period (IEP)

The Initial Enrollment Period (IEP) in insurance refers to the period during which individuals are first eligible to enroll in a particular health insurance plan, such as Medicare or a private health insurance policy. It is typically a seven-month period that begins three months before the individual's 65th birthday and ends three months after their birthday month.

Here are some key features of the Initial Enrollment Period:

• It is the first opportunity for an individual to enroll in a particular health insurance plan.

• The length of the IEP may vary depending on the type of plan and the individual's circumstances.

• It typically begins three months before the individual's 65th birthday and ends three months after their birthday month.

• During the IEP, individuals can enroll in a Medicare plan or a private health insurance policy without being subject to medical underwriting or pre-existing condition exclusions.

• If an individual misses their IEP, they may have to wait until the next open enrollment period to enroll in a health insurance plan, unless they qualify for a special enrollment period due to certain life events such as losing their job-based coverage or moving to a new area.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.